Compare Transpek Inds. with Similar Stocks
Dashboard
Company has a Debt to Equity ratio (avg) of 0.08 times
Poor long term growth as Net Sales has grown by an annual rate of 9.54% and Operating profit at 7.04% over the last 5 years
Flat results in Dec 25
With ROE of 7.6, it has a Very Attractive valuation with a 0.9 Price to Book Value
Despite the size of the company, domestic mutual funds hold only 0% of the company
Stock DNA
Commodity Chemicals
INR 660 Cr (Micro Cap)
12.00
44
1.64%
-0.08
7.57%
0.89
Total Returns (Price + Dividend) 
Risk Adjusted Returns v/s 
Returns Beta
News

Transpek Industry Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial and Technical Signals
Transpek Industry Ltd, a micro-cap player in the commodity chemicals sector, has seen its investment rating upgraded from Sell to Hold as of 6 May 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite ongoing challenges in long-term growth and recent quarterly performance.
Read full news article
Transpek Industry Ltd Technical Momentum Shifts to Sideways Amid Mixed Indicator Signals
Transpek Industry Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more neutral sideways trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, reflecting a nuanced outlook for this micro-cap commodity chemicals stock.
Read full news article
Transpek Industry Ltd is Rated Sell
Transpek Industry Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article Announcements 
Corporate Actions 
No Upcoming Board Meetings
Transpek Industry Ltd has declared 200% dividend, ex-date: 26 Aug 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 2 FIIs (0.02%)
Anshul Specialty Molecules Private Limited (24.64%)
Mukul Mahavir Agrawal (2.12%)
31.17%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is -1.12% vs 3.92% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -14.16% vs -18.87% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -0.02% vs 11.11% in Sep 2024
Growth in half year ended Sep 2025 is 49.79% vs 0.00% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -2.40% vs 12.33% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 32.49% vs -10.42% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 12.11% vs -29.90% in Mar 2024
YoY Growth in year ended Mar 2025 is 26.40% vs -53.81% in Mar 2024






